Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

bapineuzumab

Known as: Anti-human beta-amyloid Monoclonal Antibody 3D-6, Humanized 3D-6 Monoclonal Antibody 
A humanized monoclonal antibody (IgG1) raised against amyloid beta peptides with Alzheimer disease treatment application. Bapineuzumab recognizes and… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
BackgroundOur objective was to evaluate the efficacy (clinical and biomarker) and safety of intravenous bapineuzumab in patients… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Objective: To evaluate the effects of bapineuzumab on brain β-amyloid (Aβ) burden using 11C-Pittsburgh compound B (11C-PiB)-PET… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
The increasing prevalence of Alzheimer's disease represents a global challenge at multiple levels: personal, social, and economic… Expand
Is this relevant?
Highly Cited
2014
Highly Cited
2014
To the Editor: Salloway et al. (Jan. 23 issue)1 report on two trials of bapineuzumab in mild-tomoderate Alzheimer’s disease, and… Expand
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Given the slow and variable clinical course of Alzheimer disease, very large and extended clinical trials are needed… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Review
2012
Review
2012
J. Neurochem. (2012) 120 (Suppl. 1), 186–193. 
Is this relevant?
Highly Cited
2010
Highly Cited
2010
A PHASE 2 MULTIPLE ASCENDING DOSE TRIAL OF BAPINEUZUMAB IN MILD TO MODERATE ALZHEIMER DISEASE To the Editor: We read with… Expand
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Background: Bapineuzumab, a humanized anti-amyloid-beta (Aβ) monoclonal antibody for the potential treatment of Alzheimer disease… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
How reliable are mouse models of Alzheimer disease? 
Is this relevant?